Tenax Therapeutics (TENX)
NASDAQ:TENX
TENX Stock Chart & Stats
$15.02
<$0.01(0.16%)
At close: 4:00 PM EST
$15.02
<$0.01(0.16%)
Day’s Range― - ―
52-Week Range$4.63 - $18.38
Previous CloseN/A
Volume25.45K
Average Volume (3M)398.37K
Market Cap
$258.22M
Enterprise Value$160.66M
Total Cash (Recent Filing)$97.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.60
Next Earnings
May 19, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding17,197,613
10 Day Avg. Volume367,066
30 Day Avg. Volume398,365
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)4.92
Price to Sales (P/S)0.00
P/FCF Ratio-13.35
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$31.50Price Target Upside109.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Competitive DifferentiationAnalyst notes levosimendan's unique mechanism and greater reduction in pulmonary capillary wedge pressure versus sotatercept, suggesting the drug could offer a meaningful clinical advantage if Phase III confirms benefit.
Formulation And Commercial PotentialDevelopment of TNX-103 as an oral formulation, together with prior encouraging clinical data and an extended safety program, enhances commercial flexibility and regulatory appeal for the therapy.
Trial Execution And EnrollmentCompletion of enrollment and a blinded sample size reassessment showing lower-than-expected variability supports a well-powered LEVEL study and narrows the timeline for a top-line readout.
Bears Say
Clinical Endpoint SensitivityA near-stable placebo response on the six-minute walk test in CADENCE suggests difficulty demonstrating a clear treatment advantage on functional capacity in subsequent trials.
Financial RiskA negative return on equity reflects ongoing unprofitable operations and elevates funding and execution risk for continued development and commercialization efforts.
Safety And TolerabilityHigher treatment interruptions and discontinuations at the increased dose in CADENCE raise tolerability concerns that could limit dosing options or market uptake.
Tenax Therapeutics News
TENX FAQ
What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $4.63 and its highest was $18.38 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $258.22M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s upcoming earnings report date is May 19, 2026 which is in 44 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on Mar 10, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.414 by $0.034.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 17,197,613 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.414. Following the earnings report the stock price went up 31.67%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Currently, no hedge funds are holding shares in TENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenax Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.50 (109.72% Upside)
$31.50 (109.72% Upside)
Blogger Sentiment
Neutral
TENX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 494.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.33%
12-Months-Change
Fundamentals
Return on Equity
-51.83%
Trailing 12-Months
Asset Growth
7.80%
Trailing 12-Months
Company Description
Tenax Therapeutics
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
TENX Stock 12 Month Forecast
Average Price Target
$31.50
▲(109.72% Upside)
Technical Analysis
Tempest Therapeutics
―
Relmada Therapeutics
―
VYNE Therapeutics
―
Longeveron
―
Calidi Biotherapeutics
―
Ownership Overview
0.19% Insiders
1.73% Mutual Funds
22.92% Other Institutional Investors
73.52% Public Companies and
Individual Investors